Antisense Therap Ltd (ATHJF) 0.0520 $ATHJF PharmaSphere:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Antisense Therap Ltd (ATHJF) 0.0520 $ATHJF

PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis
M2 - Fri Sep 25, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nl5w7p/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report to their offering. "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, we provide an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics. Key Questions Answered - What are the drivers of the RNAi therapy field? - Who are the leading companies involved in the development of RNAi therapies? - What are the major trends in RNAi clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the antisense/RNAi therapy field? Scope - This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments - Investment examined from both industry and financial communities - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activities - Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Report Scope 2.2 Companies Mentioned 2.3 Related Reports 3 Antisense RNAi Therapy Overview 3.1 What is Antisense Therapy? 3.2 The Second Era of RNAi 4 Clinical Trials 4.1 Overview 4.2 Company 4.3 Phase of Development 4.4 Therapy Area 4.5 Indication 4.6 Investigators 5 Company Analysis 5.1 Overview 5.2 Pipeline Profiles 6 Deals Landscape 6.1 Overview 6.2 Deal Type 7 Strategic Outlook 8 Appendix Companies Featured: - Alnylam Pharmaceuticals - Antisense Therapeutics - Arrowhead Research Corporation - AuraSense Therapeutics - BioMarin Pharmaceuticals - Dicerna Pharmaceuticals - Gene Signal International SA - Idera Pharmaceuticals - InDex Pharmaceuticals AB - Isarna Therapeutics GmbH - Isis Pharmaceuticals - Miragen Therapeutics - Mirna Therapeutics - Moderna Therapeutics - Mologen AG - Oncogenex Pharmaceuticals - Quark Pharmaceuticals - Regulus Therapeutics - RXi Pharmaceuticals - Sarepta Therapeutics - Silence Therapeutics Plc - Sirnaomics - Sterna Biologicals GmbH - Sylentis SA - Tekmira (Arbutus) Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/nl...armasphere
ISIS: 43.24 (+0.86), IDRA: 3.03 (+0.10), DRNA: 10.05 (+0.88), ARWR: 5.89 (+0.13), SRPT: 37.09 (-0.72), RGLS: 6.86 (+0.29), MIRN: 6.15 (-0.08)

Diabetic Retinopathy Therapeutics Pipeline Review, H1 2015 - 34 Companies & 50 Drug Profiles
M2 - Tue Jul 21, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fgxcs/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Aprogen, Inc. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - MacuCLEAR, Inc. - MingSight Pharmaceuticals - Molecular Design International, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - PanOptica, Inc. - Promedior, Inc. - R-Tech Ueno, Ltd. - Resolvyx Pharmaceuticals, Inc - RestorGenex Corporation - Sirnaomics, Inc. - Stelic Institute & Co. - Stemedica Cell Technologies, Inc. - Targazyme, Inc. - ThromboGenics NV - TWi Pharmaceuticals, Inc. Drug Profiles - 49-B - A-6 - A-717 - AC-301 - AKB-9778 - ALG-1001 - AP-202 - ATL-1103 - BDM-E - Beta-LGND2 - CLT-01001 - CLT-01007 - CLT-01012 - cyclosporine - Cyndacel-M - DG-3173 - DMX-200 - Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - DT-23552 - E-1086 - EG-Mirotin - emixustat hydrochloride - FP-008 - IB-09A0133 - IMD-0354 - JP-153 - L-779976 - LCB-030110 For more information visit http://www.researchandmarkets.com/research/7fgxcs/diabetic
GTXI: 0.96 (unch), OHRP: 3.27 (-0.09)

Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 12.80 (+0.53), GSK: 40.22 (+0.06), XNPT: 4.19 (+0.26), SYN: 2.41 (+0.03), OPXA: 3.20 (-0.08), FWP: 27.74 (+0.87), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)

Acromegaly Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtgwjc/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - GP Pharm, S.A. - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Paladin Labs Inc. - Peptron, Inc. - Sompharmaceuticals S.A. Drug Profiles - ATL-1103 - BIM-23A758 - DG-3173 - FP-002 - G-02113 - ISIS-GHRLRx - ITF-2984 - L-779976 - octreotide - octreotide acetate - octreotide acetate LAR - octreotide acetate long acting - octreotide acetate SR - octreotide SR - pasireotide LAR - pegvisomant - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Somadex - SXN-101742 - SXN-101959 For more information visit http://www.researchandmarkets.com/research/mtgwjc/acromegaly
ISIS: 43.24 (+0.86), CHMA: 21.32 (-0.49), NVS: 91.90 (-0.71)

Antisense Therapeutics Limited - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:26AM CDT
Product Pipeline Review - 2014

Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h4bvf/proliferative) has announced the addition of the "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Proliferative Diabetic Retinopathy (PDR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Diabetic Retinopathy (PDR) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Antisense Therapeutics Limited - Icon Bioscience, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - Sirnaomics, Inc. - ThromboGenics NV Drug Profiles - ATL-1103 - BI-30089 - Lycium Anti-Angiogenic Proteoglycan - OC-10X - ocriplasmin (recombinant) - squalamine lactate - STP-601 For more information visit http://www.researchandmarkets.com/research/2h...liferative
OHRP: 3.27 (-0.09)

Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 3.11 (-0.01), GALT: 2.61 (-0.10), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CTIC: 1.63 (-0.01), CNCE: 20.87 (+0.62), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), CCXI: 6.45 (+0.02), ICPT: 181.90 (-8.81), ABBV: 55.64 (-0.40)

Cortendo and Antisense Therapeutics signs exclusive licensing agreement for ATL1103 for acromegaly
M2 - Fri May 15, 5:56AM CDT
Cortendo AB (NOTC-A:CORT) (OTC:CRTOF), a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited (ASX:ANP), an Australian biopharmaceutical drug discovery and development company, announced on Thursday the entering into an exclusive license agreement that provides Cortendo with development and commercialisation rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
CORT: 3.74 (-0.05)

Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
Business Wire - Fri May 15, 1:41AM CDT
--Cortendo Expands Investor Base Through New Private Placement

Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Business Wire - Thu May 14, 6:53PM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics' ATL1103 for endocrinology applications.

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 40.22 (+0.06), XNPT: 4.19 (+0.26), OPXA: 3.20 (-0.08), SYN: 2.41 (+0.03), ABBV: 55.64 (-0.40), TEVA: 58.96 (-0.28), NVS: 91.90 (-0.71)

Acromegaly - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqcstv/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acromegaly - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ipsen S.A. - Novartis AG - Antisense Therapeutics Limited - Paladin Labs Inc. - Camurus AB - GP Pharm, S.A. - Aegis Therapeutics, LLC - Peptron, Inc. - Q Chip Ltd. - Crinetics Pharmaceuticals, Inc. - Chiasma, Inc. - Foresee Pharmaceuticals, LLC - DexTech Medical AB For more information visit http://www.researchandmarkets.com/research/fqcstv/acromegaly
NVS: 91.90 (-0.71)

Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: 9.63 (-0.03), REGN: 503.92 (+12.71)

ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology
PR Newswire - Mon Sep 22, 8:00AM CDT
Antisense Therapeutics (the "Company" or "ANP" is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Fortune Brands' Strategic Moves for Growth and Innovation

Updated Category News Views 506

Fortune Brands Embraces Change for Future Growth Fortune Brands Innovations, Inc. (NYSE: FBIN), a leading innovation company committed to transforming spaces into havens, has announced pivotal changes aimed at enhancing its growth opportunities. These strategic moves reflect the company's dedication to innovation and efficiency as it positions itself for future success....

Continue Reading
Robert Webb's Insightful Stock Options Exercise at NHI

Updated Category News Views 97

Robert Webb Exercises Stock Options at National Health Investors Recently, an important SEC filing revealed that Robert Webb, a Board Member at National Health Investors (NHI), has exercised a significant number of stock options. Key Highlights: The latest Form 4 filing shows that Webb exercised stock options for 70,000 shares of NHI, amounting to a remarkable $1,585,550....

Continue Reading
Palantir Technologies Inc. Increases Investment in UK Defense

Updated Category News Views 271

Palantir Technologies Inc. Stock Update Recently, shares of Palantir Technologies Inc. (NASDAQ: PLTR) saw an increase of 1.58% in pre-market trading following the announcement of a substantial deal with the U.K. government. Strategic Investment in UK Defense This exciting new partnership involves Palantir committing up to £1.5 billion, equivalent to approximately $2...

Continue Reading
Investigation of Varonis Systems, Inc.: A Call to Investors

Updated Category News Views 165

Investigation into Varonis Systems, Inc. Edelson Lechtzin LLP, a well-respected national law firm, is actively investigating Varonis Systems, Inc. (NASDAQ: VRNS) due to potential violations of federal securities laws. This investigation arises from troubling allegations regarding the company's financial disclosures and communication with investors. Varonis Systems,...

Continue Reading
Error Notification on NAV Values in Wealth Invest Fund

Updated Category News Views 127

Error Notification Regarding NAV Values Nasdaq Copenhagen A/S Nikolaj Plads 6 1067 København K Important Information The latest update relates to incorrect NAV values published for the I&T Nordiske Aktier Large Cap division (ISIN: DK0061276656) of Investeringsforeningen Wealth Invest during a specific time frame. Details of the NAV Error This error occurred from 09:45 on...

Continue Reading